June 9, 2021
Clinical Oncologist at Grupo Oncoclínicas discusses phase II DESTINY-Breast01 study and meta-analysis that included four randomized clinical trials involving patients with triple-negative breast cancer The ESMO Breast Cancer 2021 event, held […]
May 24, 2021
Currently available genetic tests analyzing homologous recombination deficiency (HRD) have limited predictive value During the ESMO Breast Cancer 2021 Congress, in virtual format, a retrospective […]
May 21, 2021
Most breast cancers exhibit low T–lymphocyte infiltration and do not respond satisfactorily to immune correceptor inhibitors, leading to the need for new therapeutic strategies that act on anti-tumor immune […]
May 20, 2021
Presented during ESMO Breast Cancer 2021, meta-analysis approaches immune checkpoint inhibitors (ICIs), which have shown promising antitumor activities in several malignancies ESMO Breast Cancer 2021 starts today in virtual format, a […]
April 19, 2021
Triple-negative breast cancer is an aggressive tumor with lower overall survival compared to other types of breast malignancies. Of the 6 molecularly classified TNBC subtypes, about 10 to […]
March 31, 2021
Radiotherapy after breast-conserving surgery for the treatment of ductal carcinoma in situ (DCIS) reduces the risk of ipsilateral breast events without changing survival Between March 18th and 19th, SSO 2021 (International Conference […]
July 15, 2020
New therapeutic option for patients with high-risk HR-positive, HER2-negative breast cancer Abemaciclib in combination with standard adjuvant endocrine therapy (ET) achieved its primary objective in the […]
May 14, 2020
Approval is based on exclusive clinical trial that included patients with active brain metastases On April 17, 2020, the U.S. FDA (US Food and Drug Administration) […]
May 13, 2020
Fast Track is based on the response rate and duration of the response and reinforces the premise that the Trop-2 antigen is an important target to […]